Oncotelic Therapeutics (OTLC) News Today → The “Next Bitcoin”? 10 CENT Crypto Set to Explode (From True Market Insiders) (Ad) Free OTLC Stock Alerts $0.04 0.00 (0.00%) (As of 04/29/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisChartFinancialsHeadlinesSEC FilingsShort Interest All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineLinkage of Cancer and Lupus in Gliomas Patientsfinance.yahoo.com - March 25 at 8:20 AMLinkage of Cancer and Lupus in Gliomas Patientsglobenewswire.com - March 25 at 8:10 AMInvitation to Participate in STOP-PC Clinical Trialglobenewswire.com - March 4 at 8:17 AMOncotelic Therapeutics Stock (OTC:OTLC) Earnings Dates and Earning Callsbenzinga.com - February 22 at 11:33 PMOncotelic Therapeutics Strikes Material Definitive Legal Agreementmsn.com - February 3 at 2:28 PMLineage Cell Therapeutics Inc LCTXmorningstar.com - January 23 at 8:50 PMOncotelic Therapeutics Announces Opening of GMP Manufacturing Plantfinance.yahoo.com - December 18 at 8:33 AMOncotelic Therapeutics, Inc.: Oncotelic Reports Q3 2023 Compared to Q3 2022 Financial Resultsfinanznachrichten.de - November 15 at 3:15 PMOncotelic Therapeutics reports Q3 resultsmsn.com - November 15 at 10:15 AMOncotelic Reports Q3 2023 Compared to Q3 2022 Financial Resultsfinance.yahoo.com - November 15 at 10:15 AMThe Solid Tumors Market Is Expected To Be Worth $901.27 Billion By 2029, And Oncotelic Therapeutics (OTCQB:OTLC) Is Leading The Chargebenzinga.com - September 11 at 6:04 PMThe Solid Tumors Market Is Expected To Be Worth $901.27 Billion By 2029, And Oncotelic Therapeutics (OTCQB: OTLC) Is Helping Lead The Chargebenzinga.com - September 11 at 6:04 PMOncotelic Therapeutics, Inc. Awarded Top Cancer Immunotherapy Solutions Provider 2023finance.yahoo.com - August 25 at 9:09 AMSapu BioScience and Cromos Pharma initiating P201 – A Registrational trial for OT-101 in Pancreatic Cancerfinance.yahoo.com - August 23 at 9:05 AMOncotelic Participating at 2023 BIO International Conventionfinance.yahoo.com - May 16 at 8:20 AMOncotelic Launches PDAO SEC Chatbottechnews.tmcnet.com - April 24 at 7:46 AMOncotelic Therapeutics reports FY resultsseekingalpha.com - April 20 at 12:52 AMOncotelic Therapeutics and Vectara Announce Strategic Partnership to Transform Pharmaceutical Research with Large Language Model Technologyfinance.yahoo.com - April 19 at 9:51 AMHigh Intra-Tumor TGF-ß2 Predicts Poor Survival in Pediatric Cancer of the Brainstemtechnews.tmcnet.com - March 13 at 10:57 AMOTLC Oncotelic Therapeutics, Inc.seekingalpha.com - February 15 at 11:34 PMOncotelic Announces Initiation of Clinical Study in Non-Small Lung Cell Cancerfinance.yahoo.com - February 6 at 8:25 AMOncotelic Initiates Clinical Trials Evaluating OT-101 against Metastatic Pancreatic Cancerfinance.yahoo.com - January 25 at 9:28 AMOncotelic Issues Year End Message to Shareholdersfinance.yahoo.com - December 28 at 8:14 AMOncotelic Initiates Clinical Trials Evaluating OT-101 against Pediatric Gliomasfinance.yahoo.com - November 8 at 7:40 AMOncotelic Presenting Data for OT101 Against Pancreatic Cancer (PDAC) at the SITC 37th Annual Meetingfinance.yahoo.com - September 28 at 9:25 AMOncotelic Therapeutics, Inc. (OTLC)sg.finance.yahoo.com - September 16 at 11:01 PMOncotelic Presenting Data for OT101 Against Diffuse Intrinsic Pontine Glioma (DIPG) at the 2022 Society for Neuro-Oncology (SNO) Annual Meetingfinance.yahoo.com - September 14 at 8:45 AMOncotelic Therapeutics reports Q2 resultsseekingalpha.com - August 23 at 9:52 PMONCOTELIC REPORTS Q2 2022 COMPARED TO Q2 2021 FINANCIAL RESULTSfinance.yahoo.com - August 22 at 12:14 PMOncotelic Participating at Biotechgate Digital Partneringfinance.yahoo.com - August 17 at 11:01 AMOncotelic Announces Presentation of P001- OT-101 Phase 1/2 Trial in Pancreatic Cancerfinance.yahoo.com - July 12 at 8:28 AMOncotelic gets FDA nod for mid-stage trial design for lead asset and Keytruda comboseekingalpha.com - May 25 at 7:59 AMOncotelic Therapeutics Receives FDA Clearance for Phase 2 Clinical Trial of OT-101/Pembroluzimab Combination for Mesothelioma (M201)finance.yahoo.com - May 25 at 7:59 AMONCOTELIC PROVIDES Q1 2022 FINANCIAL RESULTS COMPARED TO Q1 2021, PRODUCT DEVELOPMENT INITIATIVES AND CORPORATE UPDATEfinance.yahoo.com - May 23 at 11:52 AMONCOTELIC ANNOUNCES US PATENT GRANT FOR CA4P AND OXI4503 COMBINATION WITH CHECKPOINT INHIBITORSfinance.yahoo.com - May 11 at 7:36 AMOncotelic Appoints Fatih Uckun, M.D., Ph.D., as Chief Medical Officerfinance.yahoo.com - May 3 at 7:40 AMONCOTELIC PROVIDES YE 2021 FINANCIAL RESULTS COMPARED TO YE 2020, PRODUCT DEVELOPMET INITIATIVES AND CORPORATE UPDATEfinance.yahoo.com - April 18 at 7:40 AMOncotelic to Present New Studies on its TGF-β Program at the American Association for Cancer Research (AACR) Annual Meeting 2022finance.yahoo.com - March 10 at 10:11 AMDr. Anthony E. Maida will be presenting at the Marcus Evans Evolution Summitfinance.yahoo.com - March 3 at 8:18 AMOncotelic Presenting at MedInvest Pharmaceutical and Biotechnology Investor Conferencefinance.yahoo.com - February 24 at 9:48 AMOncotelic Presenting at BiotechGate Digital Partneringfinance.yahoo.com - January 19 at 10:35 AMOncotelic Initiates Phase 1 Trial Evaluating CA4P in Combination with Pembrolizumab for Melanomafinance.yahoo.com - January 5 at 10:38 AMOncotelic's Dr. Anthony Maida to Present at 2nd Annual TGF-β for Immuno-Oncology Drug Development Summit in January 2022stockhouse.com - December 16 at 7:21 AMDGAP-News: Oncotelic's Dr. Anthony Maida to Present at 2nd Annual TGF-ß for Immuno-Oncology Drug Development Summit in January 2022markets.businessinsider.com - December 14 at 10:16 AMOncotelic’s Dr. Anthony Maida to Present at 2nd Annual TGF-β for Immuno-Oncology Drug Development Summit in January 2022finance.yahoo.com - December 14 at 10:16 AMOncotelic Initiates Phase 2 Trial Evaluating OT-101 in Combination with KEYTRUDA® for Mesotheliomafinance.yahoo.com - December 1 at 10:12 AMOncotelic Announces Successful Completion of the Safety Evaluation of a TGF-β Inhibitor (OT-101) and IL-2 (Aldesleukin) in Phase 1 Combination Trial in Solid Tumor Cancersfinance.yahoo.com - November 16 at 8:32 AMONCOTELIC ANNOUNCES UPDATE ON THE OT-101 CLINICAL PROGRAMS INCLUDING C001 COVID STUDYfinance.yahoo.com - October 20 at 7:36 AMONCOTELIC ACQUIRES FAST TO MARKET LATE-STAGE DRUG CANDIDATE FOR PARKINSON DISEASE, ERECTILE DYSFUNCTION, AND FEMALE SEXUAL DYSFUNCTION.finance.yahoo.com - October 4 at 8:59 AMONCOTELIC TO ACQUIRE LATE-STAGE DRUG CANDIDATE FOR PARKINSON DISEASE, ERECTILE DYSFUNCTION, AND ...apnews.com - September 2 at 4:19 AM Get Oncotelic Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for OTLC and its competitors with MarketBeat's FREE daily newsletter. Email Address The “Next Bitcoin”? 10 CENT Crypto Set to Explode (Ad)The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon… Click For My #1 FREE Crypto for 2024 OTLC Media Mentions By Week OTLC Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. OTLC News Sentiment▼-0.500.34▲Average Medical News Sentiment OTLC News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. OTLC Articles This Week▼10▲OTLC Articles Average Week Get Oncotelic Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for OTLC and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: EDSA News CRPOF News ABVC News NRBO News AYTU News KPRX News LTUS News NNVC News AVTX News TNXP News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:OTLC) was last updated on 4/30/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsAI finds its first serious applicationWall Street StarThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportCharles Payne’s Gift to Stock InvestorsUnstoppable ProsperityProtect Your Bank Account Before It’s Too LateWeiss RatingsWhy Big Pharma is Investing Billions in This BiotechBehind the MarketsHe Is Giving Away BitcoinCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncotelic Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
